Generic Mektovi Availability
Last updated on May 7, 2025.
Mektovi is a brand name of binimetinib, approved by the FDA in the following formulation(s):
MEKTOVI (binimetinib - tablet;oral)
-
Manufacturer: ARRAY BIOPHARMA INC
Approval date: June 27, 2018
Strength(s): 15MG [RLD]
Is there a generic version of Mektovi available?
No. There is currently no therapeutically equivalent version of Mektovi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mektovi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compounds and compositions as protein kinase inhibitors
Patent 10,005,761
Issued: June 26, 2018
Inventor(s): Huang Shenlin & Jin Xianming & Liu Zuosheng & Poon Daniel & Tellew John & Wan Yongqin & Wang Xing & Xie Yongping
Assignee(s): Array BioPharma Inc.The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Patent expiration dates:
- August 27, 2030✓
- August 27, 2030✓
- August 27, 2030
-
N3 alkylated benzimidazole derivatives as MEK inhibitors
Patent 7,777,050
Issued: August 17, 2010
Inventor(s): Wallace; Eli M. et al.
Assignee(s): Array BioPharma Inc. (Boulder, CO)Disclosed are compounds of the Formula I ##STR00001## and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Patent expiration dates:
- March 13, 2026✓✓
- March 13, 2026
-
Compounds and compositions as protein kinase inhibitors
Patent 9,314,464
Issued: April 19, 2016
Inventor(s): Huang Shenlin & Jin Xianming & Liu Zuosheng & Poon Daniel & Tellew John & Wan Yongqin & Wang Xing & Xie Yongping
Assignee(s): Novartis AGThe invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Patent expiration dates:
- July 4, 2031✓
- July 4, 2031✓
- July 4, 2031
-
Preparation of and formulation comprising a MEK inhibitor
Patent 9,562,016
Issued: February 7, 2017
Inventor(s): Krell; Christoph Max et al.
Assignee(s): Array BioPharma, Inc. (Boulder, CO); Novartis AG (Basel, CH)The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
Patent expiration dates:
- October 18, 2033✓✓
- October 18, 2033
-
Preparation of and formulation comprising a MEK inhibitor
Patent 9,598,376
Issued: March 21, 2017
Inventor(s): Krell; Christoph Max et al.
Assignee(s): Array BioPharma, Inc. (Boulder, CO); Novartis AG (Basel, CH)The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
Patent expiration dates:
- October 18, 2033✓
- October 18, 2033
-
Compounds and compositions as protein kinase inhibitors
Patent 9,850,229
Issued: December 26, 2017
Inventor(s): Huang Shenlin & Jin Xianming & Liu Zuosheng & Poon Daniel & Tellew John & Wan Yongqin & Wang Xing & Xie Yongping
Assignee(s): Array BioPharma, Inc.The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Patent expiration dates:
- August 27, 2030✓
- August 27, 2030
-
Preparation of and formulation comprising a MEK inhibitor
Patent 9,980,944
Issued: May 29, 2018
Inventor(s): Krell Christoph Max & Misun Marian & Niederer Daniel Andreas & Pachinger Werner Heinz & Wolf Marie-Christine & Zimmermann Daniel & Liu Weidong & Stengel Peter J. & Nichols Paul
Assignee(s): Array BioPharma Inc.The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
Patent expiration dates:
- October 18, 2033✓
- October 18, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 27, 2025 - ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
- October 11, 2026 - ENCORAFENIB IN COMBINATION WITH BINIMETINIB, IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
More about Mektovi (binimetinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.